EU/3/17/1852

About

On 20 March 2017, orphan designation (EU/3/17/1852) was granted by the European Commission to Regulatory Resources Group Ltd, United Kingdom, for allogeneic ex-vivo-expanded umbilical cord blood-derived haematopoietic CD34+ progenitor cells and allogeneic non-expanded umbilical cord blood-derived haematopoietic mature myeloid and lymphoid cells (also known as NiCord) for treatment in haematopoietic stem cell transplantation.

The sponsorship was transferred to Voisin Consulting S.A.R.L., France, in January 2019.

Key facts

Active substance
Allogeneic ex-vivo-expanded umbilical cord blood-derived haematopoietic CD34+ progenitor cells and allogeneic non-expanded umbilical cord blood-derived haematopoietic mature myeloid and lymphoid cells
Disease / condition
Treatment in haematopoietic stem cell transplantation
Date of first decision
20/03/2017
Outcome
Positive
EU designation number
EU/3/17/1852

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Voisin Consulting S.A.R.L.
64 Avenue Pierre Grenier
92100 Boulogne-Billancourt
France
Tel. +33 1413 18300
E-mail: orphan@voisinconsulting.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;

How useful was this page?

Add your rating